Corbus Pharmaceuticals Holdings Inc.

0.2518-0.0305-10.80%Vol 904.51K1Y Perf -86.36%
Jun 24th, 2022 16:00 DELAYED
BID0.2643 ASK0.2999
Open0.2957 Previous Close0.2823
Pre-Market- After-Market0.28
 - -  0.03 11.08%
Target Price
1.98 
Analyst Rating
Moderate Buy 2.33
Potential %
686.34 
Finscreener Ranking
★★★+     50.74
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★+     50.01
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★     43.82
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.33 
Earnings Rating
Buy
Market Cap31.54M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.23
Beta2.03 

Today's Price Range

0.25030.3082

52W Range

0.20802.09

5 Year PE Ratio Range

-10.80-2.80

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-16.12%
1 Month
-16.73%
3 Months
-53.89%
6 Months
-64.03%
1 Year
-86.36%
3 Years
-96.32%
5 Years
-96.03%
10 Years
-

TickerPriceChg.Chg.%
CRBP0.2518-0.0305-10.80
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
5.70
5.90
0.24
0.43
-167.80
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
-
-20 990.20
-20 313.30
-1 666.60
-
RevenueValueIndustryS&P 500US Markets
233.88K
0.00
-62.37
-18.13
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.09-0.0811.11
Q04 2021-0.11-0.0827.27
Q03 2021-0.12-0.0283.33
Q02 2021-0.12-0.15-25.00
Q01 2021-0.15-0.146.67
Q04 2020-0.22-0.1054.55
Q03 2020-0.41-0.43-4.88
Q02 2020-0.38-0.52-36.84
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.060.00-
9/2022 QR-0.060.00-
12/2022 FY-0.24-9.09Negative
12/2023 FY-0.306.25Positive
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.06
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume904.51K
Shares Outstanding125.26K
Shares Float124.71M
Trades Count1.97K
Dollar Volume253.79K
Avg. Volume903.42K
Avg. Weekly Volume599.50K
Avg. Monthly Volume675.11K
Avg. Quarterly Volume1.44M

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) stock closed at 0.2518 per share at the end of the most recent trading day (a -10.8% change compared to the prior day closing price) with a volume of 904.51K shares and market capitalization of 31.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Corbus Pharmaceuticals Holdings Inc. CEO is Yuval Cohen.

The one-year performance of Corbus Pharmaceuticals Holdings Inc. stock is -86.36%, while year-to-date (YTD) performance is -59.1%. CRBP stock has a five-year performance of -96.03%. Its 52-week range is between 0.208 and 2.09, which gives CRBP stock a 52-week price range ratio of 2.33%

Corbus Pharmaceuticals Holdings Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 0.61, a price-to-sale (PS) ratio of 160.77, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.22%, a ROC of -38.00% and a ROE of -52.87%. The company’s profit margin is -%, its EBITDA margin is -20 313.30%, and its revenue ttm is $233.88 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Corbus Pharmaceuticals Holdings Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Corbus Pharmaceuticals Holdings Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Corbus Pharmaceuticals Holdings Inc. is Moderate Buy (2.33), with a target price of $1.98, which is +686.34% compared to the current price. The earnings rating for Corbus Pharmaceuticals Holdings Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corbus Pharmaceuticals Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corbus Pharmaceuticals Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.43, ATR14 : 0.04, CCI20 : -72.49, Chaikin Money Flow : -0.06, MACD : -0.01, Money Flow Index : 43.92, ROC : -10.52, RSI : 41.88, STOCH (14,3) : 31.61, STOCH RSI : 0.47, UO : 45.85, Williams %R : -68.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corbus Pharmaceuticals Holdings Inc. in the last 12-months were: Craig Stuart Millian (Buy at a value of $3 700), Sean F. Moran (Buy at a value of $9 150), Yuval Cohen (Buy at a value of $5 807)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.33

Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

CEO: Yuval Cohen

Telephone: +1 617 963-0100

Address: 500 River Ridge Drive, Norwood 02062, MA, US

Number of employees: 141

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

57%43%

News

Stocktwits